Genocea finds targets of T cell responses to discover and develop life-changing medicines. The company created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases. Genocea designs its medicines using ATLASª, a proprietary technology platform. Genocea's platform has the potential to revolutionize vaccines and immunotherapies for a range of infectious diseases, cancers and autoimmune diseases.